ProQR Announces Third Quarter 2021 Operating and Financial Results
Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022
Five-target collaboration with Lilly highlights significant potential of ProQR’s Axiomer® RNA base-editing platform and strengthens financial position with $50 million in upfront and equity and up to $1.25 billion in milestones
QR-421a Phase 2/3 Sirius and Celeste trials in Usher syndrome and retinitis pigmentosa on track to start by year end 2021
Company to host an “Analyst Event” on November 18, 2021 to highlight clinical stage pipeline programs and Axiomer® RNA editing platform
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its financial and operating results for the third quarter ended September 30, 2021, and provided a business update.
“In the third quarter we made significant progress across our pipeline and platform to develop medicines for patients in need. We continue to be on track for the readout of the sepofarsen Illuminate trial in the first half of next year and are narrowing our guidance for this to a late Q1/early Q2 timeframe. Other significant milestones achieved in Q3, include the partnership we entered into with Lilly around our Axiomer RNA base-editing platform and the appointment of Theresa Heggie as our Chief Commercial Officer,” said Daniel A. de Boer, Founder and CEO of ProQR. “Theresa is a seasoned leader with deep rare disease experience, including the launch of multiple products. Her expertise further strengthens our team and supports our commitment to bringing our pipeline of therapies to patients with genetic eye diseases.”
De Boer continued, “More broadly, our pipeline programs are progressing as anticipated. We expect to start two Phase 2/3 trials of QR-421a in Usher syndrome and nsRP before the end of the year. In Q4 we will share an update from our QR-1123 program in adRP and our QR-504a Fuchs Focus trial is open for enrollment, representing our first corneal program.”
Business Operations and Program Updates
Sepofarsen for CEP290-mediated Leber congenital amaurosis 10 (LCA10):
The Company expects to report top-line results from the Phase 2/3 Illuminate trial in late Q1/early Q2 2022. The Illuminate trial completed enrollment in January 2021 following randomization of 36 patients aged 8 years or older to receive either sepofarsen at the target registration dose, a low dose, or sham treatment. The primary endpoint for Illuminate is mean change from baseline in best-corrected visual acuity (BCVA) at Month 12.
Enrollment is ongoing in the Phase 2/3 Brighten trial of sepofarsen in LCA10. The primary objective of this study is to evaluate safety and tolerability of sepofarsen in patients under 8 years of age.
The Company will share updated data from the Phase 1/2 InSight extension study later this month at the Analyst Event scheduled for November 18.
QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa (nsRP):
Based on the findings from the Phase 1/2 Stellar trial, the Company is advancing QR-421a into two pivotal Phase 2/3 trials – Sirius in advanced patients, and Celeste in early-moderate patients – by year end. Each trial could potentially serve as the sole registration trial.
The Company has begun enrolling eligible patients from the Phase 1/2 Stellar trial in the open-label extension study Helia, which will include multiple dose treatments for both eyes.
In September, findings from the Phase 1/2 Stellar trial were presented in an oral presentation at the European Society of Retina Specialists (EURETINA) virtual congress.
Earlier-stage clinical pipeline:
The Company anticipates sharing initial findings from the Phase 1 Aurora trial of QR-1123 for autosomal dominant retinitis pigmentosa (adRP) in Q4. Aurora is a first-in-human clinical study, designed to evaluate safety and tolerability. The Company will be looking for evidence of target engagement and/or disease modification to inform the next steps in development.
The Fuchs Focus study of QR-504a for Fuchs Endothelial Corneal Dystrophy (FECD) is currently open for enrollment. This study is evaluating safety, tolerability, and molecular biomarker(s), i.e., target engagement, in the corneal endothelium following a single intravitreal injection of QR-504a in patients with FECD who are scheduled for corneal transplant with concurrent lens replacement.
Business updates:
In September, Eli Lilly and Company (Lilly) and ProQR entered into a licensing and research collaboration related to ProQR’s proprietary Axiomer RNA base-editing platform. Under the terms of the agreement, ProQR will receive $50 million consisting of an upfront payment of $20 million, as well as an equity investment in its ordinary shares of $30 million. ProQR is eligible to receive up to approximately $1.25 billion in milestones, plus royalties.
In October, Theresa Heggie was appointed Chief Commercial Officer (CCO). As CCO, Ms. Heggie is responsible for overseeing the Company’s commercial strategy and global commercial operations. She brings extensive global rare disease commercialization experience having previously served in senior commercial and operating roles at both Alnylam Pharmaceuticals and Shire.
Upcoming Analyst Event:
ProQR will host an Analyst Event for the investment community via webcast on Thursday, November 18, from 12-2pm ET. ProQR leadership will highlight key advancements from its clinical-stage pipeline, including data from the Phase 1/2 Insight extension study of sepofarsen. The Company will also highlight the sepofarsen program more broadly, recapping data from the program to date, sharing the perspective of a patient from the Phase 1/2 trial, and reviewing the Phase 2/3 Illuminate trial design and assumptions. The QR-421a, QR-1123, QR-504a, and RNA editing programs will also be featured. The live and archived webcast will be accessible through this webcast link, or through the Events page of the Company’s website.
Financial Highlights
At September 30, 2021, ProQR held cash and cash equivalents of €156.1 million, compared to €75.8 million at December 31, 2020. Net cash used in operating activities during the three-month period ended September 30, 2021 was €8.1 million, compared to €9.8 million for the same period last year. After September 30, 2021, ProQR received an upfront payment of $20 million from Lilly related to the Axiomer licensing and research collaboration.
Research and development costs were €11.1 million for the quarter ended September 30, 2021, compared to €8.3 million for the same period last year.
General and administrative costs were €4.6 million for the quarter ended September 30, 2021 compared to €2.8 million for the same period last year.
Net loss for the three-month period ended September 30, 2021 was €15.1 million or €0.22 per share, compared to a €13.2 million loss or €0.26 per share for the same period last year.
For further financial information for the period ended September 30, 2021, please refer to the financial statements appearing at the end of this release.
About Leber Congenital Amaurosis 10 (LCA10)
Leber congenital amaurosis (LCA) is the most common cause of blindness due to genetic disease in children. It consists of a group of diseases of which LCA10 is the most frequent and one of the most severe forms. LCA10 is caused by mutations in the CEP290 gene, of which the p.Cys998X mutation has the highest prevalence. LCA10 leads to early loss of vision causing most people to lose their sight in the first few years of life. To date, there are no treatments approved that treat the underlying cause of the disease. Approximately 2,000 people in the Western world have LCA10 because of this mutation.
About Sepofarsen
Sepofarsen (QR-110) is being evaluated in the pivotal Phase 2/3 Illuminate trial and is a first-in-class investigational RNA therapy designed to address the underlying cause of Leber congenital amaurosis 10 due to the p.Cys998X mutation (also known as the c.2991+1655A>G mutation) in the CEP290 gene. The p.Cys998X mutation leads to aberrant splicing of the mRNA and non-functional CEP290 protein. Sepofarsen is designed to enable normal splicing, resulting in restoration of normal (wild type) CEP290 mRNA and subsequent production of functional CEP290 protein. Sepofarsen is intended to be administered through intravitreal injections in the eye and has been granted orphan drug designation in the United States and the European Union and received fast-track designation and rare pediatric disease designation from the FDA as well as access to the PRIME scheme by the EMA.
About Usher Syndrome Type 2a and Non-Syndromic Retinitis Pigmentosa (nsRP)
Usher syndrome is the leading cause of combined deafness and blindness. People with Usher syndrome type 2a are usually born with hearing loss and start to have progressive vision loss during adulthood. The vision loss can also occur without hearing loss in a disease called non-syndromic retinitis pigmentosa. Usher syndrome type 2a and non-syndromic retinitis pigmentosa can be caused by mutations in the USH2A gene. To date, there are no pharmaceutical treatments approved or in clinical development that treat the vision loss associated with mutations in USH2A.
About QR-421a
QR-421a is a first-in-class investigational RNA therapy designed to address the underlying cause of vision loss in Usher syndrome type 2a and non-syndromic retinitis pigmentosa due to mutations in exon 13 of the USH2A gene. QR-421a is designed to restore functional usherin protein by using an exon skipping approach with the aim to stop or reverse vision loss in patients. QR-421a is intended to be administered through intravitreal injections in the eye and has been granted orphan drug designation in the US and the European Union and received fast-track and rare pediatric disease designations from the FDA.
About Autosomal Dominant Retinitis Pigmentosa (adRP)
Autosomal dominant retinitis pigmentosa, or adRP, is a severe and rare genetic disease that causes progressive problems in night vision during childhood, leading to visual field loss and frequently resulting in blindness in mid adulthood. In the United States, the most prevalent mutation associated with adRP is the P23H point mutation (also known as the c.68C>A mutation) in the rhodopsin (RHO) gene and affects approximately 2,500 people. This mutation causes misfolding of the rhodopsin protein that becomes toxic to the photoreceptor cells and at the same time diminishes the function of the wild type allele. Over time this results in cell death and progressive vision loss. There are currently no therapies approved or in clinical development for P23H adRP. A natural history study in patients with P23H adRP has been conducted.
About QR-1123
QR-1123 is being evaluated in the Phase 1/2 Aurora trial and is a first-in-class investigational RNA therapy designed to treat adRP due to the P23H mutation in the RHO gene. QR-1123 was discovered and developed by Ionis Pharmaceuticals using Ionis’ proprietary antisense technology. The therapy aims to inhibit the formation of the mutated toxic version of the rhodopsin protein by specifically binding the mutated RHO mRNA. Binding of QR-1123 causes allele specific knockdown of the mutant mRNA by a mechanism called RNase H mediated cleavage without affecting the normal RHO mRNA. QR-1123 is intended to be administered through intravitreal injections in the eye. QR-1123 has been granted Orphan Drug designation in the United States and received Fast Track designation from the FDA.
About Fuchs Endothelial Corneal Dystrophy (FECD)
Fuchs endothelial corneal dystrophy (FECD) type 3 is a common genetic disease that leads to progressive degeneration of the corneal endothelium resulting in corneal edema, scarring and vision loss. Blisters on the cornea are a major cause of pain in patients with advanced FECD. Currently there are no treatment options available to stop or slow down FECD and disease management is aimed to reduce symptoms. The only effective therapy for late-stage FECD is corneal transplantation. The availability of donors, risk of rejection, and the inherent risk of such surgeries are some of the limitations of this option. FECD is a common disorder affecting more than 4% of people over the age of 40 in the United States, with similar numbers reported for other parts of the World. Trinucleotide repeat (TNR) expansion mutations in the TCF4 gene are a common cause of FECD. In people of European descent, around 75% of FECD patients have TNR expansions in TCF4.
About QR-504a
QR-504a is a first-in-class investigational RNA therapy designed to address the underlying cause of Fuchs endothelial corneal dystrophy (FECD) due to trinucleotide repeat (TNR) expansion mutations in the TCF4 gene. The TNR expansions cause the TCF4 RNA to aggregate in the corneal endothelial cells forming the characteristic nuclear RNA foci and eventually resulting in FECD. QR-504a is designed to target the TNRs in the TCF4 RNA. The aim is to reduce aggregation and the formation of RNA foci to prevent or stop corneal degeneration in patients with FECD. QR-504a is intended to be administered through intravitreal injections in the eye.
About Axiomer and Trident
ProQR is pioneering a next-generation RNA technology called Axiomer®, which could potentially yield a new class of medicines for genetic diseases. Axiomer “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells. The Axiomer® EONs are designed to recruit an endogenously expressed RNA editing system called ADAR, which can direct the change of an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G).
Our TRIDENT™ RNA pseudouridylation platform enables the suppression of nonsense mutations and premature stop codons (PTC) that cause human genetic diseases. Since all premature stop codons contain uridine, pseudouridylation of that uridine converts those nonsense codons into sense codons. TRIDENT technology harnesses endogenously expressed pseudouridylation machinery to guide RNAs to inhibit nonsense mRNA-mediated decay (NMD) in a sequence-specific manner and promote PTC readthrough. The TRIDENT technology has the potential to be applied in approximately 11% of all genetic mutations.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
Learn more about ProQR at www.proqr.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding sepofarsen (QR-110) and the clinical development and the therapeutic potential thereof, statements regarding QR-421a and the clinical development and the therapeutic potential thereof, statements regarding QR-1123 and the clinical development and therapeutic potential thereof, statements regarding the QR-504a and the clinical development and therapeutic potential thereof, statements regarding our pipeline of programs targeting inherited retinal dystrophies, including timing of commencing clinical trials and enrollment of patients therein, our other programs and business operations (including Axiomer and Trident), the expected impact of the COVID-19 on our business operations, including our research and development plans and timelines and the supply chain for our clinical and development programs, statements regarding the collaboration with Lilly and the intended benefits thereof, including the upfront payment, equity investment, and milestone and royalty payments from commercial product sales, if any, from the products covered by the collaboration, statements regarding information in the upcoming analyst event and our financial position and cash runway. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners whose operations and activities may be slowed or halted by the COVID-19 pandemic; the likelihood of our clinical programs being executed on timelines provided and reliance on our contract research organizations and predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; our ability to maintain and service our loan facility with Pontifax and Kreos; general business, operational, financial and accounting risks; and risks related to litigation and disputes with third parties. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
Cautionary Note on Future Updates
The statements contained in this press release reflect our current views with respect to future events, which may change significantly as the global consequences of the COVID-19 pandemic rapidly develop. Accordingly, we do not undertake and specifically disclaim any obligation to update any forward-looking statements.
ProQR Therapeutics N.V.
Investor Contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Hans Vitzthum
LifeSci Advisors
T: +1 617 430 7578
hans@lifesciadvisors.com
Media Contact:
Cherilyn Cecchini, MD
LifeSci Communications
T: +1 646 876 5196
ccecchini@lifescicomms.com
PROQR THERAPEUTICS N.V.
Unaudited Condensed Consolidated Statement of Financial Position
September 30, | December 31, | |||
2021 | 2020 | |||
€ 1,000 | € 1,000 | |||
Assets | ||||
Current assets | ||||
Cash and cash equivalents | 156,141 | 75,838 | ||
Prepayments and other receivables | 20,407 | 3,762 | ||
Social securities and other taxes | 511 | 421 | ||
Total current assets | 177,059 | 80,021 | ||
Property, plant and equipment | 17,559 | 18,601 | ||
Investments in associates | 92 | 107 | ||
Investments in financial assets | 621 | — | ||
Total assets | 195,331 | 98,729 | ||
Equity and liabilities | ||||
Equity | ||||
Equity attributable to owners of the Company | 128,606 | 57,091 | ||
Non-controlling interests | (585) | (545) | ||
Total equity | 128,021 | 56,546 | ||
Current liabilities | ||||
Borrowings | 1,791 | 1,135 | ||
Lease liabilities | 1,395 | 1,260 | ||
Derivative financial instruments | 2,263 | 839 | ||
Trade payables | 894 | 221 | ||
Current income tax liability | — | — | ||
Social securities and other taxes | 546 | 22 | ||
Pension premiums | — | 6 | ||
Deferred income | 19,987 | 700 | ||
Other current liabilities | 7,812 | 6,118 | ||
Total current liabilities | 34,688 | 10,301 | ||
Borrowings | 17,513 | 16,189 | ||
Lease liabilities | 15,109 | 15,693 | ||
Total liabilities | 67,310 | 42,183 | ||
Total equity and liabilities | 195,331 | 98,729 |
PROQR THERAPEUTICS N.V.
Unaudited Condensed Consolidated Statement of Profit or Loss and OCI
(€ in thousands, except share and per share data)
Three month period | Nine month period | |||||||
ended September 30, | ended September 30, | |||||||
2021 | 2020 | 2021 | 2020 | |||||
€ 1,000 | € 1,000 | € 1,000 | € 1,000 | |||||
Revenue | 872 | — | 1,115 | — | ||||
Other income | 286 | 251 | 838 | 9,188 | ||||
Research and development costs | (11,124) | (8,304) | (29,764) | (29,716) | ||||
General and administrative costs | (4,591) | (2,809) | (12,052) | (10,173) | ||||
Total operating costs | (15,715) | (11,113) | (41,816) | (39,889) | ||||
Operating result | (14,557) | (10,862) | (39,863) | (30,701) | ||||
Finance income and expense | 266 | (1,863) | (2,491) | (2,024) | ||||
Results related to associates | (132) | (84) | (239) | (270) | ||||
Gain on recognition of financial asset | — | — | 621 | — | ||||
Results related to financial liabilities measured at fair value through profit or loss | (611) | (305) | (1,373) | (305) | ||||
Result before corporate income taxes | (15,034) | (13,114) | (43,345) | (33,300) | ||||
Income taxes | (35) | (75) | (95) | (86) | ||||
Result for the period | (15,069) | (13,189) | (43,440) | (33,386) | ||||
Other comprehensive income (foreign exchange differences on foreign operation) | 206 | (255) | 461 | (134) | ||||
Total comprehensive income | (14,863) | (13,444) | (42,979) | (33,520) | ||||
Result attributable to | ||||||||
Owners of the Company | (15,047) | (13,181) | (43,400) | (33,348) | ||||
Non-controlling interests | (22) | (8) | (40) | (38) | ||||
(15,069) | (13,189) | (43,440) | (33,386) | |||||
Total comprehensive income attributable to | ||||||||
Owners of the Company | (14,841) | (13,436) | (42,939) | (33,482) | ||||
Non-controlling interests | (22) | (8) | (40) | (38) | ||||
(14,863) | (13,444) | (42,979) | (33,520) | |||||
Share information | ||||||||
Weighted average number of shares outstanding1 | 68,263,034 | 50,143,262 | 61,804,367 | 50,017,990 | ||||
Earnings per share attributable to owners of the Company (Euro per share) | ||||||||
Basic loss per share1 | (0.22) | (0.26) | (0.70) | (0.67) | ||||
Diluted loss per share1 | (0.22) | (0.26) | (0.70) | (0.67) | ||||
For these periods the potential exercise of share options is not included in the diluted earnings per share as the Company was loss-making. Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal.
PROQR THERAPEUTICS N.V.
Unaudited Condensed Consolidated Statement of Changes in Equity
Attributable to owners of the Company | ||||||||||||||||||||
Number | Share | Share | Equity settled | Option | Translation | Accumulated | Total | Non- | Total | |||||||||||
€ 1,000 | € 1,000 | € 1,000 | € 1,000 | € 1,000 | € 1,000 | € 1,000 | € 1,000 | € 1,000 | ||||||||||||
Balance at January 1, 2020 | 53,975,838 | 2,159 | 287,214 | 16,551 | — | 151 | (211,746) | 94,329 | (496) | 93,833 | ||||||||||
Result for the period | — | — | — | — | — | — | (33,348) | (33,348) | (38) | (33,386) | ||||||||||
Other comprehensive income | — | — | — | — | — | (134) | — | (134) | — | (134) | ||||||||||
Recognition of share-based payments | — | 2 | 283 | 6,218 | — | — | — | 6,503 | — | 6,503 | ||||||||||
Issuance of ordinary shares | 100,902 | 2 | 270 | — | — | — | — | 272 | — | 272 | ||||||||||
Treasury shares transferred | (299,615) | — | — | — | — | — | — | — | — | — | ||||||||||
Recognition of equity component of convertible loan | — | — | — | — | 280 | — | — | 280 | — | 280 | ||||||||||
Share options lapsed | — | — | — | (63) | — | — | 63 | — | — | — | ||||||||||
Share options exercised | 299,615 | — | 724 | (466) | — | — | 466 | 724 | — | 724 | ||||||||||
Balance at September 30, 2020 | 54,076,740 | 2,163 | 288,491 | 22,240 | 280 | 17 | (244,565) | 68,626 | (534) | 68,092 | ||||||||||
Balance at January 1, 2021 | 54,131,553 | 2,165 | 288,757 | 23,825 | 280 | (189) | (257,747) | 57,091 | (545) | 56,546 | ||||||||||
Result for the period | — | — | — | — | — | — | (43,400) | (43,400) | (40) | (43,440) | ||||||||||
Other comprehensive income | — | — | — | — | — | 461 | — | 461 | — | 461 | ||||||||||
Recognition of share-based payments | 112,657 | 5 | 382 | 4,435 | — | — | — | 4,822 | — | 4,822 | ||||||||||
Issuance of ordinary shares | 20,498,451 | 820 | 107,657 | — | — | — | — | 108,477 | — | 108,477 | ||||||||||
Treasury shares transferred | (217,933) | — | — | — | — | — | — | — | — | — | ||||||||||
Share options lapsed | — | — | — | (391) | — | — | 391 | — | — | — | ||||||||||
Share options exercised | 338,653 | 5 | 1,150 | (821) | — | — | 821 | 1,155 | — | 1,155 | ||||||||||
Balance at September 30, 2021 | 74,863,381 | 2,995 | 397,946 | 27,048 | 280 | 272 | (299,935) | 128,606 | (585) | 128,021 | ||||||||||
PROQR THERAPEUTICS N.V.
Unaudited Condensed Consolidated Statement of Cash Flows
Three month period | Nine month period | |||||||
ended September 30, | ended September 30, | |||||||
2021 | 2020 | 2021 | 2020 | |||||
€ 1,000 | € 1,000 | € 1,000 | € 1,000 | |||||
Cash flows from operating activities | ||||||||
Net result | (15,069) | (13,189) | (43,440) | (33,386) | ||||
Adjustments for: | ||||||||
— Depreciation | 544 | 651 | 1,777 | 1,703 | ||||
— Share-based compensation | 1,716 | 1,676 | 4,435 | 6,348 | ||||
— Other income | — | — | — | (8,423) | ||||
— Financial income and expenses | (266) | 1,863 | 2,491 | 2,024 | ||||
— Results related to associates | 132 | 84 | 239 | 270 | ||||
— Gain on recognition of financial asset | — | — | (621) | — | ||||
— Results related to financial liabilities measured at fair value through profit or loss | 611 | 305 | 1,373 | 305 | ||||
— Net foreign exchange gain / (loss) | 206 | (255) | 461 | (134) | ||||
— Income tax expenses | 35 | 75 | 95 | 86 | ||||
Changes in working capital | 4,630 | (321) | 5,197 | (3,440) | ||||
Cash used in operations | (7,461) | (9,111) | (27,993) | (34,647) | ||||
Corporate income tax paid | (35) | (157) | (95) | (168) | ||||
Interest received | — | 27 | 5 | 118 | ||||
Interest paid | (561) | (569) | (1,714) | (607) | ||||
Net cash used in operating activities | (8,057) | (9,810) | (29,797) | (35,304) | ||||
Cash flow from investing activities | ||||||||
Purchases of property, plant and equipment | (175) | (264) | (259) | (806) | ||||
Net cash used in investing activities | (175) | (264) | (259) | (806) | ||||
Cash flow from financing activities | ||||||||
Proceeds from issuance of shares, net of transaction costs | 23,223 | — | 108,477 | — | ||||
Proceeds from exercise of share options | 402 | 12 | 1,155 | 724 | ||||
Proceeds from borrowings | 284 | — | 853 | 579 | ||||
Proceeds from convertible loans | — | 13,477 | — | 13,542 | ||||
Repayment of lease liability | (347) | (235) | (597) | (542) | ||||
Net cash generated by financing activities | 23,562 | 13,254 | 109,888 | 14,303 | ||||
Net decrease in cash and cash equivalents | 15,330 | 3,180 | 79,832 | (21,807) | ||||
Currency effect cash and cash equivalents | 1,369 | (1,474) | 471 | (1,296) | ||||
Cash and cash equivalents, at beginning of the period | 139,442 | 87,141 | 75,838 | 111,950 | ||||
Cash and cash equivalents at the end of the period | 156,141 | 88,847 | 156,141 | 88,847 | ||||
